Ramdev, Balkrishna Acharya Ready For ‘Public Apology’; Supreme Court Next Hearing On April 23

New Delhi: The Supreme Court on Tuesday granted a week to Yoga guru Ramdev and Patanjali Ayurved Ltd MD Balkrishna Acharya to take steps to redeem themselves of the alleged contempt after their lawyers offered to issue a public apology for misleading advertisements.

“I am willing to give a public apology,” senior advocate Mukul Rohatgi, appearing for Ramdev and Balkrishna, told a bench of Justices Hima Kohli and Ahsanuddin Amanullah, news agency PTI reported.

The Supreme Court court asked Ramdev and Balkrishna, both of whom were present in the court, to come forward for an interaction with the bench.

“They should feel they have a connect with the court,” the bench said.

The hearing in the matter is underway and the bench is currently interacting with Ramdev.

Ramdev and Balkrishna have tendered an “unconditional and unqualified apology” before the apex court over advertisements issued by the firm making tall claims about the medicinal efficacy of its products.

In two separate affidavits filed in the court, Ramdev and Balkrishna have tendered an unqualified apology for the “breach of the statement” recorded in the November 21 last year order of the apex court.

In the November 21, 2023 order, the top court had noted that counsel representing Patanjali Ayurved had assured it that “henceforth there shall not be any violation of any law(s), especially relating to advertising or branding of products manufactured and marketed by it and, further, that no casual statements claiming medicinal efficacy or against any system of medicine will be released to the media in any form”.

The top court had said Patanjali Ayurved Ltd is “bound down to such assurance”.

The non-observance of the specific assurance and the subsequent media statements irked the apex court, which later issued a notice to them to explain why contempt proceedings be not initiated against them.

Related Posts

Cancer cure must not be hostage to Big Pharma

In recent years, immunotherapy has expanded the limits of cancer treatment. Therapies that harness the body’s immune system to fight malignant cells have improved survival rates in cancers once considered…

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Pune:- A woman, 34, dia­gnosed with poly­cystic ovary syn­drome, or PCOS, as a teen­ager, saw her first nat­ural men­strual cycle in Feb­ru­ary—six months after start­ing Moun­jaro for weight man­age­ment. This…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients